Natco Pharma Ltd.

Natco Pharma along with its marketing partner Arrow International (an affiliate of Teva Pharmaceutical Industries) has launched the first generic version of Revlimid (Lenalidomide capsules) in 5mg, lOmg, lSmg, and 25mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment. Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.